The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume -, Issue -, Pages 1-16
Publisher
Informa UK Limited
Online
2021-04-15
DOI
10.1080/17460441.2021.1916465
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bile acids and their receptors in metabolic disorders
- (2021) Stefano Fiorucci et al. PROGRESS IN LIPID RESEARCH
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
- (2020) Donatella Chianelli et al. JOURNAL OF MEDICINAL CHEMISTRY
- A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
- (2020) Kris V. Kowdley et al. JOURNAL OF HEPATOLOGY
- Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
- (2020) Stefano Fiorucci et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs
- (2020) Jose Miguel Ramos Pittol et al. GASTROENTEROLOGY
- Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis
- (2020) Adriana Carino et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
- (2020) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- Bile Acid Signaling in Inflammatory Bowel Diseases
- (2020) Stefano Fiorucci et al. DIGESTIVE DISEASES AND SCIENCES
- Biological Functions of Autophagy Genes: A Disease Perspective
- (2019) Beth Levine et al. CELL
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch
- (2019) James Meixiong et al. IMMUNITY
- MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus
- (2019) James Meixiong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation
- (2019) Adriana Carino et al. Nutrients
- Obeticholic acid may increase the risk of gallstone formation in susceptible patients
- (2019) Samer Al-Dury et al. JOURNAL OF HEPATOLOGY
- Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
- (2019) Michael Trauner et al. Lancet Gastroenterology & Hepatology
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis
- (2018) B. Hameed et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Farnesoid X receptor modulators 2014-present: a patent review
- (2018) Valentina Sepe et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Bile Acids Activated Receptors Regulate Innate Immunity
- (2018) Stefano Fiorucci et al. Frontiers in Immunology
- Small Heterodimer Partner and Fibroblast Growth Factor 19 Inhibit Expression of NPC1L1 in Mouse Intestine and Cholesterol Absorption
- (2018) Young-Chae Kim et al. GASTROENTEROLOGY
- Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
- (2017) Harald Staiger et al. ENDOCRINE REVIEWS
- Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice
- (2017) Jan Freark de Boer et al. GASTROENTEROLOGY
- Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism
- (2017) Preeti Pathak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis
- (2017) Michele Biagioli et al. JOURNAL OF IMMUNOLOGY
- Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review
- (2017) Duminda Suraweera et al. LIVER INTERNATIONAL
- Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties
- (2016) Olaf Kinzel et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
- (2016) JE Edwards et al. CTS-Clinical and Translational Science
- An Intestinal Farnesoid X Receptor–Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
- (2016) Cen Xie et al. DIABETES
- An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
- (2016) Frank J. Gonzalez et al. GASTROENTEROLOGY
- Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis
- (2016) Divya P. Kumar et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state
- (2016) Dandan Guan et al. Journal of Translational Medicine
- A new frontier in FGF21 biology
- (2016) Matthew J. Potthoff Nature Reviews Endocrinology
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis
- (2016) Kathleen R. Markan et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Fibroblast Growth Factor Signaling in Metabolic Regulation
- (2016) Vera J. M. Nies et al. Frontiers in Endocrinology
- Role of FXR in β-Cells of Lean and Obese Mice
- (2015) Björn Schittenhelm et al. ENDOCRINOLOGY
- Farnesoid X receptor modulators (2011 – 2014): a patent review
- (2015) Valentina Sepe et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application
- (2015) Valentina Sepe et al. Future Medicinal Chemistry
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Retinoic acid receptors: From molecular mechanisms to cancer therapy
- (2015) Alessandra di Masi et al. MOLECULAR ASPECTS OF MEDICINE
- Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases
- (2015) Fangfang Zhang et al. MOLECULAR ENDOCRINOLOGY
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
- (2015) Mohamed-Sami Trabelsi et al. Nature Communications
- Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
- (2015) Changtao Jiang et al. Nature Communications
- Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism
- (2015) Jorge C. Correia et al. Molecular Metabolism
- Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
- (2014) Ffolliott M. Fisher et al. GASTROENTEROLOGY
- Transcriptional regulation of autophagy by an FXR–CREB axis
- (2014) Sunmi Seok et al. NATURE
- Nutrient-sensing nuclear receptors coordinate autophagy
- (2014) Jae Man Lee et al. NATURE
- Dual Activation of the Bile Acid Nuclear Receptor FXR and G-Protein-Coupled Receptor TGR5 Protects Mice against Atherosclerosis
- (2014) Shinobu Miyazaki-Anzai et al. PLoS One
- Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition
- (2013) Javier Vaquero et al. BIOCHEMICAL PHARMACOLOGY
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- The TGR5 receptor mediates bile acid–induced itch and analgesia
- (2013) Farzad Alemi et al. JOURNAL OF CLINICAL INVESTIGATION
- Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor
- (2013) Xiulong Song et al. JOURNAL OF LIPID RESEARCH
- Understanding nuclear receptor form and function using structural biology
- (2013) Fraydoon Rastinejad et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes
- (2013) S. Caron et al. MOLECULAR AND CELLULAR BIOLOGY
- A Ceramide-Centric View of Insulin Resistance
- (2012) Jose A. Chavez et al. Cell Metabolism
- Bile Acids Acutely Stimulate Insulin Secretion of Mouse -Cells via Farnesoid X Receptor Activation and KATP Channel Inhibition
- (2012) M. Dufer et al. DIABETES
- Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice
- (2012) Bo Kong et al. HEPATOLOGY
- Orphan Nuclear Receptor Small Heterodimer Partner Negatively Regulates Growth Hormone-mediated Induction of Hepatic Gluconeogenesis through Inhibition of Signal Transducer and Activator of Transcription 5 (STAT5) Transactivation
- (2012) Yong Deuk Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter
- (2011) Barbara Renga et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
- (2011) Matthew J. Potthoff et al. Cell Metabolism
- Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
- (2011) J. Prawitt et al. DIABETES
- FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
- (2011) S. Kir et al. SCIENCE
- A Role of the Bile Salt Receptor FXR in Atherosclerosis
- (2010) Jurre Hageman et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The bile acid sensor FXR regulates insulin transcription and secretion
- (2010) Barbara Renga et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
- (2010) G. Rizzo et al. MOLECULAR PHARMACOLOGY
- The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice
- (2010) Andrea Mencarelli et al. PLoS One
- Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins
- (2009) Kari E. Wong et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia
- (2009) Mark J. Evans et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
- (2009) Charles Thomas et al. Cell Metabolism
- FXR an emerging therapeutic target for the treatment of atherosclerosis
- (2009) Andrea Mencarelli et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis
- (2009) A. Mencarelli et al. JOURNAL OF IMMUNOLOGY
- The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity
- (2009) P. Vavassori et al. JOURNAL OF IMMUNOLOGY
- Glucose stimulates cholesterol 7α-hydroxylase gene transcription in human hepatocytes
- (2009) Tiangang Li et al. JOURNAL OF LIPID RESEARCH
- Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice
- (2009) Changcheng Zhou et al. JOURNAL OF LIPID RESEARCH
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- (2009) Philippe Lefebvre et al. PHYSIOLOGICAL REVIEWS
- Bile acid-activated receptors in the treatment of dyslipidemia and related disorders
- (2009) Stefano Fiorucci et al. PROGRESS IN LIPID RESEARCH
- Antiatherosclerotic effect of farnesoid X receptor
- (2008) Andrea Mencarelli et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
- (2008) Cédric Langhi et al. FEBS LETTERS
- Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression
- (2008) Kwang-Hoon Song et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started